中华皮肤科杂志
中華皮膚科雜誌
중화피부과잡지
Chinese Journal of Dermatology
2013年
8期
588-590
,共3页
目的 观察白芍总苷联合依巴斯汀治疗慢性特发性荨麻疹的临床疗效和安全性.方法 采用随机、开放、阳性药物、平行对照研究方法,按随机数字表将60例慢性特发性荨麻疹患者随机分为2组,联合治疗组30例,口服白芍总苷600 mg每日3次,依巴斯汀10 mg/d;对照组口服依巴斯汀10 mg/d.疗程12周,停药后观察4周,以7d荨麻疹活动评分(UAS7)评价疗效,记录不良反应.结果 治疗第8周、第12周、停药第4周(第16周),联合治疗组UAS7(分别为9.28±4.59、5.83±4.44、7.52±5.57)明显低于对照组(分别为13.29±4.72、9.86±5.46、16.21±5.34),两组差异均有统计学意义.在治疗第12周时,联合治疗组有效率(75.9％)明显高于对照组(42.9％),差异有统计学意义(x2=4.56,P＜0.05).停药后第4周,联合治疗组复发率(13.6％)明显低于对照组(50.0％),差异有统计学意义(x2 =3.90,P＜0.05).两组未见明显不良反应.结论 白芍总苷能够明显提高依巴斯汀治疗慢性特发性荨麻疹的疗效,并降低复发率.
目的 觀察白芍總苷聯閤依巴斯汀治療慢性特髮性蕁痳疹的臨床療效和安全性.方法 採用隨機、開放、暘性藥物、平行對照研究方法,按隨機數字錶將60例慢性特髮性蕁痳疹患者隨機分為2組,聯閤治療組30例,口服白芍總苷600 mg每日3次,依巴斯汀10 mg/d;對照組口服依巴斯汀10 mg/d.療程12週,停藥後觀察4週,以7d蕁痳疹活動評分(UAS7)評價療效,記錄不良反應.結果 治療第8週、第12週、停藥第4週(第16週),聯閤治療組UAS7(分彆為9.28±4.59、5.83±4.44、7.52±5.57)明顯低于對照組(分彆為13.29±4.72、9.86±5.46、16.21±5.34),兩組差異均有統計學意義.在治療第12週時,聯閤治療組有效率(75.9％)明顯高于對照組(42.9％),差異有統計學意義(x2=4.56,P＜0.05).停藥後第4週,聯閤治療組複髮率(13.6％)明顯低于對照組(50.0％),差異有統計學意義(x2 =3.90,P＜0.05).兩組未見明顯不良反應.結論 白芍總苷能夠明顯提高依巴斯汀治療慢性特髮性蕁痳疹的療效,併降低複髮率.
목적 관찰백작총감연합의파사정치료만성특발성담마진적림상료효화안전성.방법 채용수궤、개방、양성약물、평행대조연구방법,안수궤수자표장60례만성특발성담마진환자수궤분위2조,연합치료조30례,구복백작총감600 mg매일3차,의파사정10 mg/d;대조조구복의파사정10 mg/d.료정12주,정약후관찰4주,이7d담마진활동평분(UAS7)평개료효,기록불량반응.결과 치료제8주、제12주、정약제4주(제16주),연합치료조UAS7(분별위9.28±4.59、5.83±4.44、7.52±5.57)명현저우대조조(분별위13.29±4.72、9.86±5.46、16.21±5.34),량조차이균유통계학의의.재치료제12주시,연합치료조유효솔(75.9％)명현고우대조조(42.9％),차이유통계학의의(x2=4.56,P＜0.05).정약후제4주,연합치료조복발솔(13.6％)명현저우대조조(50.0％),차이유통계학의의(x2 =3.90,P＜0.05).량조미견명현불량반응.결론 백작총감능구명현제고의파사정치료만성특발성담마진적료효,병강저복발솔.
Objective To evaluate the efficacy and safety of total glucosides of paeony combined with ebastine for the treatment of chronic idiopathic urticaria.Methods A randomized,open-labeled,positive drugcontrolled,parallel-group study was carried out.Sixty patients with chronic idiopathic urticaria were randomly divided into two groups using a random digit table:combined group treated with total glucosides of paeony 600 mg thrice daily combined with ebastine 10 mg per day,control group treated with ebastine 10 mg per day only.The treatment lasted 12 weeks followed by a four-week follow-up.Adverse reactions were recorded and treatment efficacy was evaluated by using urticaria activity score over seven days (UAS7).Results The UAS7 was 9.28 ±4.59,5.83 ± 4.44 and 7.52 ± 5.57 in the combined group on week 8,12 after the initiation of treatment and week 4 after the withdrawal of treatment,respectively,significantly lower than that in the control group at the three time points (13.29 ± 4.72,P ＜ 0.05; 9.86 ± 5.46,P ＜ 0.01; 16.21 ± 5.34,P ＜ 0.01).Significant differences were observed in the response rate between the combined group and control group at the end of the 12-week treatment (75.9％ vs.42.9％,x2 =4.56,P ＜ 0.05).There was a decreased recurrence rate in the combined group combined with the control group at the end of the follow-up (13.6％ vs.50.0％,x2 =3.90,P ＜0.05).No obvious adverse reactions were noted in either of the two groups.Conclusion Total glucosides of paeony could markedly enhance the efficacy of ebastine for the treatment of chronic idiopathic urticaria with a reduction in recurrence rate.
